By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Science are discussed in a new report. According to news originating from Charleston, South Carolina, by NewsRx correspondents, research stated, "Pregnancy represents a dynamic period with physical and physiological changes in both the mother and her developing fetus. The dramatic 2-3 fold increase in the active hormone 1,25(OH)D concentrations during the early weeks of pregnancy despite minimal increased calcium demands during that time of gestation and which are sustained throughout pregnancy in both the mother and fetus suggests an immunomodulatory role in preventing fetal rejection by the mother."
Our news journalists obtained a quote from the research from the Medical University of South Carolina, "While there have been numerous observational studies that support the premise of vitamin D's role in maintaining maternal and fetal well-being, until recently, there have been few randomized clinical trials with vitamin D supplementation. One has to exhibit caution, however, even with RCTs, whose results can be problematic when analyzed on an intent-to-treat basis and when there is high non-adherence to protocol (as if often the case), thereby diluting the potential good or harm of a given treatment at higher doses. As such, a biomarker of a drug or in this case 'vitamin' or pre-prohormone is better served. For these reasons, the effect of vitamin D therapies using the biomarker circulating 25(OH)D is a far better indicator of true 'effect.' When pregnancy outcomes are analyzed using the biomarker 25(OH)D instead of treatment dose, there are notable differences in maternal and fetal outcomes across diverse racial/ethnic groups, with improved health in those women who attain a circulating 25(OH)D concentration of at least 100 nmol?L (40 ng?mL). Because an important issue is the timing or initiation of vitamin D treatment/supplementation, and given the potential effect of vitamin D on placental gene expression and its effects on inflammation within the placenta, it appears crucial to start vitamin D treatment before placentation (and trophoblast invasion); however, this question remains unanswered. Additional work is needed to decipher the vitamin D requirements of pregnant women and the optimal timing of supplementation, taking into account a variety of lifestyles, body types, baseline vitamin D status, and maternal and fetal vitamin D receptor (VDR) and vitamin D binding protein (VDBP) genotypes."
According to the news editors, the research concluded: "Determining the role of vitamin D in nonclassical, immune pathways continues to be a challenge that once answered will substantiate recommendations and public health policies."
For more information on this research see: New insights into the vitamin D requirements during pregnancy. Bone Research, 2017;5():17030 (see also Science).
The news correspondents report that additional information may be obtained from B.W. Hollis, Dept. of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC, United States.
Keywords for this news article include: Science, Charleston, United States, South Carolina, Article Review, Risk and Prevention, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC